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Abstract
Background: Neuroinflammation and nitroxidative stress are implicated in the pathophysiology of neuropathic
pain. In view of both processes, microglial and astroglial activation in the spinal dorsal horn play a predominant
role. The present study investigated the severity of neuropathic pain and the degree of glial activation in an
inflammatory- and nitroxidative-prone animal model.
Methods: Transgenic rats expressing mutated superoxide dismutase 1 (hSOD1G93A) are classically used as a model
for amyotrophic lateral sclerosis (ALS). Because of the associated inflammatory- and nitroxidative-prone properties,
this model was used to study thermal and mechanical hypersensitivity following partial sciatic nerve ligation
(PSNL). Next to pain hypersensitivity assessment, microglial and astroglial activation states were moreover
characterized, as well as inflammatory marker gene expression and the glutamate clearance system.
Results: PSNL induced thermal and mechanical hypersensitivity in both wild-type (WT) and transgenic rats.
However, the degree of thermal hypersensitivity was found to be exacerbated in transgenic rats while mechanical
hypersensitivity was only slightly and not significantly increased. Microglial Iba1 expression was found to be
increased in the ipsilateral dorsal horn of the lumbar spinal cord after PSNL but such Iba1 up-regulation was
enhanced in transgenic rats as compared WT rats, both at 3 days and at 21 days after injury. Moreover, mRNA
levels of Nox2, a key enzyme in microglial activation, but also of pro-inflammatory markers (IL-1b and TLR4) were
not modified in WT ligated rats at 21 days after PSNL as compared to WT sham group while transgenic ligated rats
showed up-regulated gene expression of these 3 targets. On the other hand, the PSNL-induced increase in GFAP
immunoreactivity spreading that was evidenced in WT rats was unexpectedly found to be attenuated in transgenic
ligated rats. Finally, GLT-1 gene expression and uptake activity were shown to be similar between WT sham and
WT ligated rats at 21 days after injury, while both parameters were significantly increased in the ipsilateral dorsal
region of the lumbar spinal cord of hSOD1G93A rats.
Conclusions: Taken together, our findings show that exacerbated microglial activation and subsequent
inflammatory and nitroxidative processes are associated with the severity of neuropathic pain symptoms.
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Background
Neuropathic pain is characterized by altered processing
of nociceptive signals, mainly at the “first pain synapse”
located at the level of the spinal dorsal horn. A prime
role is commonly assigned to glial cells, surrounding
these “first pain synapses” [1,2]. Particularly, microglia
and astroglia have been shown to play pivotal roles in
the onset and maintenance of pain hypersensitivity after
peripheral nerve injury [3]. In healthy conditions, micro-
glia ensure immunosurveillance of the central nervous
system (CNS) [4] and astroglia, among others, regulate
synaptic transmission through active clearance of ions
and neurotransmitters [5]. Upon nerve injury however,
glial cells become activated, as classically characterized
by hypertrophied morphology, increased proliferation
and up-regulation of specific markers, like ionized-cal-
cium binding adaptor molecule 1 (Iba1) for microglia,
or glial fibrillary acidic protein (GFAP) for astroglia
[6,7]. Among many different glial activation states, some
have been specifically related to neuropathic pain [8],
characterized notably by up-regulation of pro-inflamma-
tory proteins such as Toll-like receptor 4 (TLR4) [9] or
NADPH oxidase 2 (Nox2) [10]. Moreover, the release of
the pro-inflammatory cytokine interleukin 1b (IL-1b)
was also found to contribute to pain hypersensitivity
[11]. In addition, activation of astrocytes may interfere
with the capacity of these cells to buffer the excitatory
transmitter glutamate, through altered expression and/
or function of astroglial glutamate transporters, GLAST
and GLT-1, thereby affecting the pain synapse [12-14].
Although glial activation, and more specifically subse-
quent neuroinflammation and nitroxidative stress are
known to strongly contribute to neuropathic pain
[15-17], it remains unknown whether such parameters
may influence the severity of pain symptoms. We herein
addressed this issue by studying nerve injury induced-
hypersensitivity in a rat model characterized by inflam-
matory- and nitroxidative-prone properties.
Classically used as a model for amyotrophic lateral
sclerosis (ALS), transgenic rats expressing the mutated
form of the human superoxide dismutase 1 (hSOD1G93A
[18] showing a toxic gain of function [19]) are character-
ized by excitotoxic insults and increased nitroxidative
stress [20,21]. The high vulnerability of motor neurons to
these pathological processes explains their progressive loss
in adulthood, leading to paralysis and death from respira-
tory failure. Previous studies have indicated that cultured
glial cells derived from the hSOD1G93A model are more
inclined to get activated, and once activated, the release of
neuroactive mediators is amplified [22-24]. We therefore
hypothesized that performing a peripheral nerve injury in
hSOD1G93A rats early before the onset of any symptom,
will cause exacerbated glial responses and subsequently,
an increased neuroinflammatory and nitroxidative
environment in the spinal cord, with putative influence on
the severity of neuropathic pain symptoms. All experi-
ments were completed within the pre-symptomatic stage
of transgenic animals, as no symptom of the disease (such
as motor deficit or weight loss) can be detected before 150
days (unpublished observation, Goursaud S.). Both wild-
type (WT) and transgenic rats aged 90 days underwent
partial sciatic nerve ligation (PSNL) to study thermal and
mechanical hypersensitivity up to 21 days after surgery. In
addition, biochemical studies were performed to charac-
terize microglial and astroglial activation states as well as
inflammatory processes and regulation in the glutamate
clearance system in the dorsal spinal cord.
Methods
General
All experiments were strictly performed respecting the
European Community Council directive of 24 November
1986 (86-609/ECC) and the decree of 20 October 1987
(87-848/EEC). Transgenic Sprague-Dawley rats expres-
sing hSOD1G93A (multiple copies of the transgene, [25])
were kindly provided by Dr R. Pochet (Université Libre
de Bruxelles, Belgium). Noteworthy and as commonly
documented [26], the phenotype of the rats in our col-
ony underwent a drift over multiple consecutive genera-
tions, leading to a postponed onset (150 days of age)
and a slow disease progression. Animals were kept in
controlled conditions (temperature, relative humidity, 12
h light/dark cycle) with constant access to food and
water. To identify transgenic rats, tail biopsies from
newborn rat pups (5-7 days old) were used, and the pre-
sence of the transgene was probed by PCR on genomic
DNA extracts as previously described [27].
In this study, a total of 93 Sprague-Dawley female rats
(females are characterized by a later ALS onset, [28])
were used, of which 46 were wild-type (WT) and 47
were transgenic (hSOD1G93A positive, heterozygous).
When the experiments started, all rats were aged 90
days and all experiments were completed within the
pre-symptomatic stage.
First, the inflammatory-prone phenotype of the trans-
genic rats was investigated in our experimental para-
digm. PSNL [29] or sham surgeries were performed on
WT and transgenic rats that were sacrificed on post-
operative day 3 or 21 to study microglial Iba1 gene
expression. A second cohort of animals was used to
monitor thermal and mechanical hypersensitivity for 21
days after surgery. After sacrifice, spinal tissues were
analyzed for cellular and molecular changes related to a
neuroactive environment (microglial and astroglial acti-
vation, expression of inflammatory markers) as well as
for the study of glutamate transporters. All experiments
were performed in a blinded manner, where the experi-
menters were unaware of experimental conditions.
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Animal surgeries
At 90 days of age, WT or hSOD1G93A female rats were
anesthetized with sevoflurane (8% for induction; 4% for
maintenance; oxygen as carrier gas) and a PSNL was
performed as previously described, with slight modifica-
tions [29]. Briefly, the right sciatic nerve was exposed at
the mid-thigh level after isolation from the surrounding
tissues. With a 6-0 suture, one third to one half of the
nerve was tightly ligated at the site corresponding to the
nerve trunk above its bifurcation in peroneal and tibial
branches. Muscle and skin layers were finally closed
with a 2-0 suture. Sham surgeries were performed by
simply exposing the nerve before suturing the wound
without performing the ligation.
Behavioral testing
During the 2 weeks preceding surgeries, all animals used
for behavioral analyses were habituated to the testing
procedures.
To examine thermal hyperalgesia (Hargreaves test),
rats were placed in separate transparent boxes, for at
least 15 min before starting measurements. A beam of
radiant heat was applied to the mid plantar surface of
rat’s hind paws (Paw Thermal Stimulator, San Diego
University, USA) and paw withdrawal latencies (PWL)
were measured for the ipsilateral and the contralateral
sides, with a cut-off fixed at 20 s to avoid tissue damage.
For each time-point, the PWL of at least four testing
trials, each separated by a 10 min interval, were aver-
aged per rat and normalized by the rat’s own average
PWL before surgery (baseline).
To assess mechanical allodynia (von Frey hair filament
tests), rats were placed in the same boxes, on a metal
mesh floor for at least 15 min to let them habituate to
the experimental environment. The previously described
up-down method was used with minor modifications to
determine the 50% paw withdrawal threshold (PWT,
[30]). In total, 9 different von Frey filaments (Stoelting
Co, Dale, USA) were selected, with bending force from
0.4 g to 26 g. The filaments were applied perpendicu-
larly to the mid plantar surface of hind paws until bend-
ing, for 8 s. A response was considered as positive only
if the rat showed paw withdrawal with clear signs of
aversion against the stimulus (i.e. postural movement,
licking of the paw, maintaining the paw in up-lift
position).
One day before surgery, baseline values were obtained
for each rat. Post-operative assessments of pain behavior
were performed on day 1, 2, 3, 5, 7, 10, 14, 17 and 20
post-surgery.
Fresh tissue dissection
Rats were euthanized with CO2 and decapitated. The
spinal cord was rapidly isolated by hydro-extrusion and
transferred to cooled phosphate-buffered saline (PBS)
solution to carefully remove meninges. The lumbar
enlargement (L3-L6) was isolated and ipsilateral and
contralateral sides were separated using the ventral fis-
sure as a reference. Subsequently, these halves were
divided into dorsal and ventral parts using the central
canal as a reference. For measurement of glutamate
transporter activity (synaptosomes, see below), fresh tis-
sue samples were used immediately. For quantitative
PCR (qPCR) experiments, tissues were frozen in 1 mL
TriPure isolation reagent (Roche, Mannheim, Germany)
before further use.
RNA extraction, reverse transcription and real-time qPCR
After thawing of samples, the ipsilateral dorsal quadrant
of the lumbar spinal cord was mechanically dissociated
in TriPure isolation reagent, followed by RNA extraction
according to the manufacturer’s protocol. Reverse tran-
scription was carried out with 1 μg of RNA using the
iScript cDNA synthesis kit (BioRad, Nazareth, Belgium),
in a total volume of 20 μL. Real-time qPCR were finally
performed to specifically amplify Iba1, glutamate trans-
porters (GLAST and GLT-1), cytokines (IL-1b), TLR4,
Nox2 and GAPDH (see Table 1). Reactions were carried
out in a total volume of 25 μL, containing 2 ng of
cDNA sample, 350 nM of both specific forward and
reverse primers and the IQ SYBR® Green supermix 1 ×
(BioRad, 100 mM KCl, 40 mM Tris-HCl pH 8.4, 0.4
mM each dNTP, 50 U/ml of iTaq DNA polymerase, 6
mM MgCl2, SYBR Green I, 20 nM fluorescein, stabili-
zers). The protocol consisted of 45 amplification cycles,
each characterized by 15 s of denaturation at 95°C, 45 s
of hybridization at 60°C and 15 s of elongation at 79°C.
The measurements were performed using the iCycler IQ
multicolor real-time PCR detection system, while the
analysis of raw data was performed via the “post run
data analysis” software provided by BioRad.
Table 1 Real-time qPCR primers (F: forward primer, R:
reverse primer) and size of amplicon
Gene Sequence Amplicon (bp)
GAPDH F: 5’- GTCTCCTGTGACTTCAACAG -3’
R: 5’- AGTTGTCATTGAGAGCAATGC -3’
76
Iba1 F: 5’- CAGAATGATGCTGGGCAAG -3’
R: 5’- CCTCCAATTAGGGCAACTCA -3’
127
GLAST F: 5’- GATCGGAAACATGAAGGAGC -3’
R: 5’- CAAGAAGAGGATGCCCAGAG -3’
121
GLT-1 F: 5’- GGTCAATGTAGTGGGCGATT -3’
R: 5’- GGACTGCGTCTTGGTCATTT -3’
124
Nox2 F: 5’- CCTTTCCTGCATCTGGGTCTCC -3’
R: 5’- CGCCCTTTGCCTCCATTCTC -3’
164
IL-1b F: 5’- GGAAGGCAGTGTCACTCATTGTG -3’
R: 5’- GGTCCTCATCCTGGAAGCTCC -3’
84
TLR4 F: 5’- GATTGCTCAGACATGGCAGTTTC -3’
R: 5’- CACTCGAGGTAGGTGTTTCTGCTAA -3’
135
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For quantification, a relative standard curve was gen-
erated for each targeted gene by using a cDNA template
mix (combining all experimental samples) used at serial
dilutions. After plotting the threshold values of amplifi-
cations versus the logarithm of the amount of cDNA
added for the reaction, the relative amount of the tar-
geted gene in each sample condition was calculated.
Values were finally normalized against the relative
expression of the housekeeping gene GAPDH.
Measurement of D-[3H]-aspartate uptake activity in spinal
cord synaptosomes
After dissection, fresh tissue was immediately used to
prepare synaptosomes, as previously described [31], with
few modifications. The ipsilateral and contralateral dor-
sal part of the lumbar (L3-L6) spinal cord were homoge-
nized in 5 mL of ice-cold (4°C) 0.32 M sucrose solution
by repeating 10 up-and-down movements in a pre-
chilled Teflon glass homogenizer. The homogenates
were then centrifuged at 1000 g for 10 min at 4°C, and
only the supernatants, containing the synaptosomes,
were collected and stored on ice, while the pellets were
resuspended in 5 mL of fresh 0.32 M sucrose solution
at 4°C. After 10 up-and-down movements, the homoge-
nates were again centrifugated at 1000 g for 10 min at
4°C. Supernatants were pooled and finally centrifuged at
17500 g for 30 min at 4°C. After discarding the superna-
tants, the pellets, containing the synaptosomes vesicles,
were homogenized with 10 up-and-down strokes in 500
μL of a Krebs-ringer buffer (120 mM NaCl, 4.8 mM
KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4,
25 mM NaHCO3, 6 mM glucose, pH 7.6) at 4°C. Protein
concentrations were determined for each sample with
the Bradford method. To assess glutamate transporter
activity, D-[3H]-aspartate (specific activity of 11.3 Ci/
mmol, PerkinElmer NEN, Zaventem, Belgium) was used
as substrate (as aspartate and glutamate have similar
affinities for glutamate transporters), at a tracer concen-
tration of 50 nM. In a total volume of 500 μL, 40 μg of
protein (synaptosome preparation) were then incubated
with the substrate for 10 min at 37°C. To evaluate the
GLT-1-dependent uptake, the specific inhibitor dihydro-
kainic acid (DHK, 100 μM, Tocris, Bristol, UK) was
added to the reaction. The suspension was immediately
filtered through a GF/B glass fiber filter adapted 96-well
plate (UniFilter GF/B, PerkinElmer), and washed three
times with the Krebs-Ringer buffer at 4°C. Filters were
then dried overnight at 37°C. Microscint 20 (45 μL, Per-
kinElmer) was then added to each well of the filter
plate, and after 24 h, plates were counted with a Top-
count® Microplate scintillation and luminescence coun-
ter (PerkinElmer). Results are expressed as pmol of D-
[3H]-aspartate transported per min and per mg of
protein.
Immunohistochemistry and quantification
On day 21 post-surgery, rats were anesthetized using keta-
mine (80 mg/kg) and xylazine (10 mg/kg), and then sacri-
ficed by transcardiac perfusion with saline solution (NaCl
0.9%) at 37°C, followed by perfusion with paraformalde-
hyde solution (4% PFA in PBS buffer) at 4°C. The spinal
cord was isolated via hydro-extrusion and stored overnight
in the PFA solution for a post-fixation at 4°C. Cryopreser-
vation was performed by incubation in a 15% sucrose solu-
tion (in PBS buffer) for 24 h at 4°C, followed by incubation
in a 30% sucrose solution for 3 consecutive days at 4°C.
The lumbar region of each spinal cord (L3-L6) was frozen
using dry ice. The samples were finally stored at -80°C
until cryosectioning. In total, 20 spinal cord samples were
serially cut at -30°C to obtain twelve series of transverse
30 μm thick sections which were collected on Thermo-
Scientific superfrost Plus glass slides (VWR International,
Leuven, Belgium). Sections were stored at -20°C until
further histological staining. After thawing and drying,
every 12th section was stained for Iba1 or GFAP. For Iba1,
sections were washed 3 times (3 × 10 min) under gentle
shaking, in Tris-buffered saline (TBS) (pH 7.6), before
incubation in a blocking solution (5% normal donkey
serum (NDS), 1% Triton X-100, in TBS pH 7.6) for 1 h at
4°C. The primary antibody against Iba1 (rabbit anti-rat
Iba1, 1:1000, Wako Pure Chemical Ltd, Osaka, Japan), was
diluted in a working solution containing 1% NDS and 1%
Triton X-100 (in TBS, pH 7.4), for an overnight incubation
at 4°C. The next day, after 3 washing steps (3 × 10 min)
with TBS, sections were incubated with secondary anti-
body (donkey anti-rabbit-Alexa488 antibody, 1:100, Invi-
trogen, Merelbeke, Belgium) diluted in the same working
solution, for 1 h at 4°C. After 3 washes in TBS (3 × 10
min), sections were embedded in 80% glycerol in PBS, and
finally cover-slipped.
The protocol of GFAP staining was similar, except for
the washing buffer (use of TBS-T: TBS containing 0.3%
of Triton X-100), the absence of a blocking step, and
the antibody incubation conditions (use of a TBS-T
solution containing the primary antibody rabbit anti-rat
GFAP 1:1000 from DAKO Diagnostics, Heverlee, Bel-
gium, and the overnight incubation at room tempera-
ture). The secondary antibody (donkey anti-rabbit-
Alexa488 antibody, 1:100, Invitrogen) was diluted in a
TBS-T solution for 1 h at room temperature. Sections
were finally embedded and cover-slipped.
Photo-micrographs of the ipsilateral and contralateral
dorsal horns were taken using a fluorescent microscope
(Olympus Ax70, Paes, Zoeterwoude, The Netherlands)
with a 4x-objective and a grey-scale F-view cooled CCD
camera. A total of 10 sections (L4-L5) per animal were
analyzed using the cell profiler software CellP® (Olym-
pus). The dorsal horn was delineated and after back-
ground subtraction, Iba1 and GFAP stained dorsal
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horns were analyzed. The percentage of dorsal horn
showing positive immunostaining, also referred as “area
fraction” (AF) was calculated for each photo-micro-
graphs and data were finally plotted in a graph.
Statistical analyses
Data were expressed as means ± standard error of the
mean (SEM) and statistical analysis were performed
with GraphPad Prism version 3.02 (GraphPad software,
CA, USA). To compare the 4 different groups, a one-
way ANOVA followed by the Tukey post-hoc test for
multiple comparisons were used. A repeated measures
ANOVA followed by a Tukey post-hoc test was used to
compare the severity of pain hypersensitivity between
WT and hSOD1G93A animals. Values of p< 0.05 were
considered as statistically significant. Symbols * were
used to compare WT ligated vs WT sham rats, symbols
$ were used to compare transgenic ligated vs transgenic
sham rats, and finally, symbols # were used to compare
WT ligated vs transgenic ligated rats. Two symbols indi-
cate a p value < 0.01 while 3 symbols represent a p
value < 0.001.
Results
Up-regulation of Iba1 gene expression is enhanced in
hSOD1G93A rats at 3 and at 21 days after PSNL
Quantitative RT-qPCR measurements of the microglial
marker Iba1 were performed on spinal cord samples in
order to evaluate the inflammatory response after PSNL
(Figure 1). Ipsilateral lumbar dorsal quadrants were dis-
sected from WT or transgenic rats, at 3 days and at 21
days after surgery. At the early post-operative time-
point (Figure 1A), WT ligated rats showed only a dis-
crete increase in Iba1 mRNA levels as compared to
their control group. In contrast, transgenic ligated rats
showed a clear and statistically significant increase in
gene expression of the microglial marker. The increase
in Iba1 gene expression induced by PSNL was moreover
significantly higher in transgenic rats as compared to
WT animals. Importantly, mRNA expression of Iba1 did
not differ between sham groups. At 21 days post surgery
(Figure 1B), Iba1 gene expression appeared significantly
increased in both ligated groups, but mRNA levels were
clearly and significantly higher in samples from trans-
genic ligated rats when compared with WT ligated rats.
Gene expression of the microglial marker was again
found to be similar between both WT and transgenic
sham groups.
Rats expressing hSOD1G93A show enhanced pain
hypersensitivity after PSNL
Hypersensitivity to thermal and mechanical stimulation
of hind paws was monitored during 21 days after sham
or PSNL surgery, in both WT and transgenic rats
(Figure 2). Noteworthy, uninjured WT and hSOD1G93A
rats showed similar baseline paw withdrawal latencies
(PWL) and paw withdrawal thresholds (PWT). After
PSNL however, a clear and significant decline in the
withdrawal latency after thermal stimulation of ipsilat-
eral hind paws was observed in ligated animals in com-
parison with their respective sham group (Figure 2A).
Importantly, no difference in the PWL could be detected
between both WT and transgenic sham groups through-
out the period of thermal pain hypersensitivity assess-
ment. The response was moreover unilateral as the
withdrawal latency of contralateral paws was unaffected
for both WT and hSOD1G93A rats (Figure 2B). Interest-
ingly, thermal pain hypersensitivity after PSNL was
more pronounced for transgenic compared to WT ani-
mals. Area under the curve analysis confirmed the sig-
nificantly enhanced ipsilateral thermal pain
hypersensitivity for transgenic ligated rats as compared
to WT ligated rats (Figure 2E), while contralateral values
were unchanged (Figure 2F).
Consistent with data from thermal stimulation,
mechanical pain hypersensitivity testing indicated that
PSNL caused a robust decrease in the ipsilateral 50%
PWT (Figure 2C) while no difference was observed on
the contralateral side (Figure 2D). Both sham-operated
groups showed similar 50% PWT until the endpoint of
mechanical pain hypersensitivity testing. However, the
ipsilateral 50% PWT did not differ between WT and




































Figure 1 Iba1 gene expression is enhanced in hSOD1G93A rats
at 3 and 21 days after PSNL. Iba1 mRNA expression (normalized
for GAPDH mRNA expression) is strongly increased in the ipsilateral
dorsal quadrant of the lumbar spinal cord of transgenic rats at 3
days (A) and at 21 days (B) after PSNL, as compared to WT ligated
animals, validating the inflammatory-prone phenotype of hSOD1G93A
rats after peripheral nerve injury. Each group included 5 animals, ##
p< 0.01, $$$ p< 0.001, *** p< 0.001, ### p< 0.001 after ANOVA and
Tukey post-hoc test.
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Figure 2 Rats expressing hSOD1G93A show enhanced pain hypersensitivity after PSNL. Rats were tested for thermal and mechanical
hypersensitivity for 21 days after surgery. Paw withdrawal latencies (PWL) of the ipsilateral (A) or contralateral (B) hind paws after thermal
stimulation, expressed as a percentage of the baseline PWL. PSNL induced a decrease of PWL in both WT and hSOD1G93A rats on the ipsilateral
side, compared to their respective sham controls (statistics not shown). The ANOVA repeated measures revealed enhanced pain hypersensitivity
for hSOD1G93A rats compared to WT rats after PSNL. (C,D) 50% paw withdrawal threshold (PWT) of the ipsilateral (C) or contralateral (D) hind
paws after mechanical stimulation, expressed in grams. PSNL triggered mechanical hypersensitivity in both WT and transgenic rats (statistics not
shown), but no statistical difference was evidenced between WT and transgenic rats after ligation. (E-H) Area under the curve (AUC) analysis of
the corresponding graph confirmed the enhanced ipsilateral thermal hypersensitivity in transgenic rats compared to WT rats after PSNL (#p <
0.05), while mechanical hypersensitivity only tends to be amplified in transgenic rats after lesion (p = 0.08); ANOVA and Tukey post-hoc test.
Each group included 6 to 8 animals.
Berger et al. Journal of Neuroinflammation 2011, 8:33
http://www.jneuroinflammation.com/content/8/1/33
Page 6 of 14
curve analysis of the ipsilateral side (Figure 2G) indi-
cated a trend (p< 0.08) towards a difference between
WT ligated and hSOD1G93A ligated animals. No changes
were noticed in the area under the curve analysis for the
contralateral side (Figure 2H).
Rats expressing hSOD1G93A show enhanced Iba1 protein
up-regulation at 21 days after PSNL in the dorsal horn of
the spinal cord
Immunohistochemical analysis of Iba1 protein expres-
sion was performed on lumbar spinal cord sections
from rats sacrificed at 21 days after surgery. In both
WT and hSOD1G93A sham-operated groups, microglia
were characterized as small and ramified cells (Figure
3A and 3B). Similar observations were made in the con-
tralateral dorsal horn of WT rats with sham or PSNL
surgery (data not shown). In contrast, a marked increase
in Iba1 immunoreactivity was evidenced in the ipsilat-
eral dorsal horn of both WT and hSOD1G93A ligated
groups, where microglia were typically hypertrophied
and less ramified (Figure 3C and 3D). To a lower extent,
such hypertrophied microglia were also observed in the
contralateral dorsal horn of the hSOD1G93A rats with
PSNL (data not shown). Quantitative analyses showed
that the ipsilateral Iba1 area fraction was higher for rats
with PSNL as compared to sham operated-rats. This dif-
ference was statistically significant for transgenic ani-
mals (p< 0.001) and showed a trend towards statistical
significance for WT animals (Figure 3E). Overall, ipsilat-
eral Iba1 protein expression associated with PSNL was
found to be stronger in hSOD1G93A rats as compared to
WT animals (p< 0.05). Analysis of the contralateral dor-
sal horn demonstrated that PSNL significantly increased
Iba1 area fraction in transgenic animals only (Figure
3F). Ipsilateral and contralateral Iba1 area fraction of the
dorsal lumbar spinal horn were moreover found to be
similar between both WT and transgenic sham groups.
Finally, ipsilateral Iba1 area fraction values were inter-
estingly found to be correlated (p < 0.001) with the per-
centage of change of the ipsilateral PWL from the
baseline, on post-operative day 21 (Figure 3G). Note-
worthy, as the PSNL damages both sensory and motor
neuron processes in the sciatic nerve, increased Iba1
immunoreactivity was logically observed in the ipsilat-
eral ventral horn of WT and transgenic ligated animals,
though such responses were not further quantified.
Rats expressing hSOD1G93A show impaired GFAP protein
up-regulation at 21 days after PSNL in the dorsal horn of
the spinal cord
Immunodetection of GFAP expression was also per-
formed on lumbar spinal cord sections in order to char-
acterize the spreading of the astroglial response induced
by PSNL in WT and hSOD1G93A rats (Figure 4A-D).
Figure 3 Increased Iba1 protein up-regulation in transgenic
rats at 21 days after PSNL. (A-D) Immunohistological staining of
the microglial marker Iba1 at 21 days after surgery, on the ipsilateral
side of the lumbar spinal cord with a low and high magnification.
(A,B) Microglia in both WT (A) and transgenic (B) sham groups
showed a ramified morphology. After PSNL, microglia exhibited a
hypertrophied morphology, an effect which was found to be
stronger in transgenic rats (D) as compared to WT rats (C) (scale bar
represents 500 μm). (E,F) Quantification of the percentage of the
total dorsal horn showing positive Iba1 immunostaining. On the
ipsilateral side (E), Iba1 protein up-regulation was found to be
stronger in transgenic compared to WT rats after PSNL ($$$ p<
0.001; # p< 0.05). The contralateral side (F) showed a modest Iba1
up-regulation only in transgenic rats at 21 days after PSNL ($ p<
0.05; ## p< 0.01). (G) The percentage of change in PWL from
baseline on post-operative day 21 appeared to be correlated with
the level of Iba1 up-regulation (R2 = 0.63 and p< 0.001). WT groups
included 4 animals whereas hSOD1G93A groups included 6 animals;
ANOVA and Tukey post-hoc test for statistical analyses.
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Three weeks after lesion, GFAP immunoreactivity was
found to be similar in the ipsilateral dorsal horn of both
sham groups (Figure 4A and 4B), while the signal was
clearly increased only in WT rats after ligation. With
respect to cell morphology, immunoreactive cells
appeared hypertrophied only in WT injured animals
(Figure 4C), while few changes were observed in
hSOD1G93A ligated rats (Figure 4D). Quantitative analy-
sis of the area fraction of the ipsilateral dorsal horns
from GFAP staining revealed significant increase follow-
ing PSNL only for WT animals. For the transgenic
model, GFAP area fraction was modestly but not signifi-
cantly increased in comparison with sham littermates
(Figure 4E). In the contralateral dorsal horn, no statisti-
cal changes could be detected for all animal groups (Fig-
ure 4F). Finally, no significant correlation was observed
between ipsilateral GFAP area fraction and PWL on
post-operative day 21 (Figure 4G). Here again, PSNL
resulted in astroglial activation in the ipsilateral ventral
horn of both WT and transgenic rats.
Glutamate transporter expression and activity are
increased after PSNL in hSOD1G93A rats
Changes in glial glutamate handling likely contribute to
altered pain transmission in the spinal cord of animals
with peripheral nerve injuries. Therefore, the expression
and activity of the two key glial glutamate transporters
were compared in samples from WT and transgenic ani-
mals after PSNL. Quantitative PCR revealed that no sig-
nificant changes in GLAST and GLT-1 mRNA levels
were detected at 21 days after lesion in the ipsilateral
dorsal quadrant of the lumbar spinal cord of WT rats.
In contrast, a discrete but significant increase in GLAST
expression was observed when comparing the groups of
ligated animals (Figure 5A). Such difference was even
more pronounced for GLT-1, as statistical analysis
revealed increased expression associated with PSNL in
transgenic rats when compared either to transgenic
sham littermates or to WT ligated rats (Figure 5B).
Quantitative measures of aspartate uptake in synapto-
somes prepared from lumbar dorsal spinal cord samples
were performed in order to evaluate changes in the
activity of glutamate transporters. Consistent with the
increased gene expression of the transporters, increased
uptake was measured in ipsilateral samples from
hSOD1G93A ligated rats whereas no change was
observed for WT ligated animals (Figure 6A). In the
tested conditions, GLT-1-dependent uptake (estimated
using the specific blocker DHK) accounted for approxi-
mately 25% of total uptake. The use of this blocker evi-
denced that DHK-sensitive uptake was statistically
increased only in samples from hSOD1G93A injured rats
but not in WT ligated animals (Figure 6C). For both
WT and hSOD1G93A ligated groups, neither the total
Figure 4 GFAP protein up-regulation is attenuated in
hSOD1G93A rats at 21 days after PSNL. (A-D) Immunohistological
staining of the astroglial marker GFAP at 21 days after surgery, on
the ipsilateral side of the lumbar spinal cord with a low and high
magnification. (A,B) Astrocytes in the ipsilateral dorsal horn of WT
(A) or transgenic (B) rats after sham operation showed a typical
star-shaped morphology. At 21 days after PSNL, WT rats showed a
strong astroglial response, characterized by cell hypertrophy and
increased GFAP staining (C). In transgenic rats, this astroglial
response was clearly attenuated (D) (scale bar represents 500 μm).
(E,F) Quantification of the percentage of the total dorsal horn
showing positive GFAP immunostaining. GFAP protein up-regulation
was validated on the ipsilateral side (E) only for WT ligated rats,
while transgenic rats showed a modest but non-significant increase
in GFAP expression after PSNL. The contralateral side (F) did not
show any statistical changes in GFAP area fraction. (G) The
percentage of change in PWL from baseline on post-operative day
21 did not correlate with the level of GFAP up-regulation (R2 =
0.02). WT groups included 4 rats whereas hSOD1G93A groups
included 6 rats; ANOVA and Tukey post-hoc test for statistical
analyses.
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uptake nor the DHK-sensitive uptake were altered in
samples from the contralateral dorsal horns (Figure 6B
and D). Importantly, both gene expression and uptake
capacities were found similar between WT and
hSOD1G93A sham groups.
Increased gene expression of Nox2, IL-1b and TLR4 at 21
days after PSNL in hSOD1G93A rats
To assess microglial activation, Nox2 mRNA (catalytic
subunit gp91phox) [10] was quantified in the ipsilateral
dorsal quadrant of the lumbar spinal cord at 21 days
after surgery. While no difference could be detected
between both sham groups, PSNL was shown to induce
an increase in Nox2 gene expression. However, Nox2
mRNA up-regulation was found to be significant only
for transgenic ligated rats when compared to their
respective sham group, but also to WT ligated animals
(Figure 7A). Because TLRs have previously been incrimi-
nated in neuropathic pain and TLR4 is the best charac-
terized member of this family [9,32], TLR4 gene
expression was measured in the ipsilateral dorsal quad-
rant of the lumbar spinal cord at 21 days after surgery.
At this time-point, TLR4 mRNA levels appeared
strongly increased in transgenic ligated rats as compared
to the other groups. In contrast, no significant PSNL
induced-increase in this pro-inflammatory receptor was
detected in WT rats (Figure 7B). Pro-inflammatory cyto-
kines are moreover clearly incriminated in neuropathic
pain [33] and more precisely, IL-1b was shown to be a
key cytokine in the development and maintenance of
pain hypersensitivity [11]. Hence, gene expression of IL-
1b was also quantified in the ipsilateral dorsal lumbar
samples. Similarly, a substantial increase in IL-1b tran-
scripts was only evidenced in transgenic animals after
ligation when compared to the other groups (Figure 7C).
Discussion
Microglial activation and subsequent neuroinflamma-
tory/nitroxidative processes are known to directly influ-
ence neuropathic pain, however, such parameters were
never studied after peripheral nerve injury in an animal
model showing exacerbated inflammatory and nitroxida-
tive properties, such as hSOD1G93A rats. First, we were
able to verify that at the age chosen, uninjured trans-
genic rats did not differ from WT rats in baseline pain
behavior. Second, no differences were observed between
both WT and transgenic sham groups for all biochem-
ical parameters tested in the dorsal region of the lumbar
spinal cord. The present study demonstrates that in
transgenic rats expressing hSOD1G93A, PSNL leads to:
(1)- increased microglial Iba1 up-regulation at early (day
3 post surgery) and late (day 21 post surgery) time-
points; (2)- enhanced pain hypersensitivity; (3)- impaired
astrogliosis at 21 days after lesion; (4)- increased expres-
sion and function of the glutamate transporters GLAST
and GLT-1 at 21 days after injury; and (5)- increased
gene expression of Nox2, TLR4 and IL-1b at 21 days
after nerve injury.
Inflammatory reactions are exacerbated in the dorsal
spinal cord of hSOD1G93A rats after peripheral nerve
injury
Over-expression of hSOD1G93A was already associated
with inflammatory-prone properties in in vitro studies.
Exposure of hSOD1G93A-derived glial cells to an activat-
ing stimulus indeed leads to enhanced production of
pro-inflammatory mediators and increased protein car-
bonylation, as compared to activated glia from control
animals [22-24]. We here provide the first evidence that














































Figure 5 hSOD1G93A rats show higher mRNA levels of the
glutamate transporters GLAST and GLT-1 after PSNL. (A) mRNA
expression of the glutamate transporter GLAST (normalized for
GAPDH mRNA expression) is slightly increased in the ipsilateral
dorsal horn of transgenic rats when compared to WT animals at 21
days after PSNL (#p< 0.05). (B) mRNA levels of the glutamate
transporter GLT-1 after GAPDH normalization are higher in the
ipsilateral dorsal horn of transgenic rats at 21 days after PSNL when
compared to the sham control rats or to WT ligated rats ($$$ p<
0.001, # p< 0.05). Each group included 5 animals, ANOVA and Tukey
post-hoc test for statistical analyses.
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upon peripheral nerve injury, as evidenced by enhanced
Iba1 gene up-regulation as early as 3 days after PSNL.
Moreover, the neuropathy-induced increase in Iba1 gene
and protein expression was also found to be exacerbated
in transgenic rats at 21 days after PSNL, reinforcing the
statement that microglial activation in hSOD1G93A rats
is clearly amplified upon injury.
The underlying mechanisms of exacerbated microglial
responses may originate from the activating mutation of
hSOD1, causing an imbalance in the redox equilibrium
that ultimately promotes the expression and release of
pro-inflammatory mediators, as well as reactive oxygen/
nitrogen species (ROS/RNS), after glial activation
[22,23,34]. Importantly, similar Iba1 expression was
measured for WT and hSOD1G93A sham animals on
postoperative day 3 (mRNA level) and 21 (mRNA and
protein levels), implicating that exacerbated activation is
not observed in the absence of lesion. Furthermore, it
also highlights that at this early pre-symptomatic stage
of ALS, there is no glial activation and no molecular
changes in the dorsal region of the lumbar spinal cord,
as previously reported [35]. The effects obtained after
PSNL appear therefore independent of the development
of ALS.
hSOD1G93A rats develop enhanced pain hypersensitivity
after PSNL
In comparison with WT rats, hSOD1G93A animals
showed enhanced thermal hypersensitivity following
PSNL, while the increase in mechanical hypersensitivity
was only mild and did not reach statistical significance.
This discrepancy may be explained by a biased floor
effect in the assessment of mechanical sensitivity, as

















































































Figure 6 hSOD1G93A rats show increased glutamate uptake capacities after PSNL. (A, B) Measure of the total uptake activity in the
ipsilateral (A) and the contralateral (B) dorsal quadrant of the lumbar spinal cord, expressed in pmol of D-[3H]-aspartate transported per min and
per mg of proteins. Transgenic rats only showed a higher uptake capacity at 21 days after surgery when compared to their sham control group
($ p< 0.05) and to the WT ligated group (# p< 0.05) on the ipsilateral (A) side. No changes were found on the contralateral (B) side. (C, D)
Measure of the DHK-sensitive uptake activity in the ipsilateral (C) or the contralateral (D) dorsal horn of the lumbar spinal cord, expressed in
pmol of D-[3H]-aspartate transported per min and per mg of proteins. (C) In the ipsilateral dorsal quadrant, the DHK-sensitive uptake was found
highly increased in hSOD1G93A rats at 21 days after ligation when compared to sham control rats ($$$ p< 0.001) or to WT ligated rats (### p<
0.001). The DHK-sensitive uptake was unaffected on the contralateral side (D). Each group included 5 rats, ANOVA and Tukey post-hoc test as
statistical analyses.
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animals. Alternatively, a differential mechanism may
underlie thermal as opposed to mechanical hypersensi-
tivity. It is indeed proposed that mechanical hypersensi-
tivity requires a specific population of unmyelinated
fibers [36] while thermal hypersensitivity is dependent
on the expression of a specific protein in nociceptors
[37]. Thermal and mechanical hypersensitivities were
moreover shown to be regulated by different pathways
in an aquaporin-4 KO animal model [38] or after phar-
macological treatment with ROS scavengers [10].
While microglial activation is known to contribute to
the development of neuropathic pain [3,39], it has also
been suggested to participate in the maintenance of this
hypersensitive condition [40]. Hence, the increased
PSNL induced-hypersensitivity in transgenic rats may
reflect the activation state adopted by microglia in the
dorsal horn of the spinal cord. Indeed, different activa-
tion states of microglia have been documented, suggest-
ing that their response is specialized and dictated by the
nature of the stimulus [41]. Only some of these pheno-
typic changes have been directly linked to neuropathic
pain and have been qualified as “pain-related” [8].
Hence, it may be proposed that the activation state
reached by microglia after PSNL differs between WT
and transgenic rats, with distinct consequences on the
severity of pain symptoms. Indeed, hSOD1G93A rats did
not only show increased microglial activation, as evi-
denced with Iba1 gene and protein up-regulation, but
also an increased gene expression of TLR4, which was
absent in WT ligated rats. Because microglial TLR4 is
linked to inflammation and pain [9], its high expression
at late time-points supports the idea that hSOD1G93A
microglia adopt an exacerbated “pain-related” activation
state after nerve injury. PSNL was moreover found to
induce increased expression of the pro-inflammatory
cytokine IL-1b in transgenic, but not in WT animals
after 3 weeks. This cytokine was also clearly linked to
neuropathic pain [42,43] and may therefore participate
in the enhanced pain hypersensitivity observed in trans-
genic rats. Finally, ROS production associated with
Nox2 activity was previously shown to be critical for
pain hypersensitivity, but also for the production of pro-
inflammatory mediators [10]. Because transgenic rats
show enhanced Nox2 gene expression after PSNL as
compared to WT ligated rats, we conclude that the
increased ROS production together with the exacerbated
inflammatory reactions may contribute to the enhanced
pain hypersensitivity. However, we cannot exclude the
possibility that beside glial cells, inherent changes in
dorsal horn sensory neurons due to hSOD1G93A expres-
sion, are to some extent involved in the increased pain
effects.
Surprisingly, we did not observe mirror-pain after
PSNL. Although PSNL was originally associated with
mirror-pain [29], works from different laboratories
frequently led to inconsistent results [44-46]. Interest-
ingly, we observed a modest microglial Iba1 up-regula-
tion in the contralateral dorsal horn of transgenic rats.
This observation supports the concept dissociating





































































Figure 7 hSOD1G93A rats show increased gene expression of
Nox2, TLR4 and IL-1b at 21 days after PSNL. (A) mRNA levels of
Nox2 (normalized for GAPDH mRNA expression) are higher in the
ipsilateral dorsal quadrant of the lumbar spinal cord of transgenic
rats at 21 days after PSNL, when compared to the other groups ($$
$ p< 0.001; ## p< 0.01). (B) TLR4 gene expression was also
increased in transgenic rats at 21 days after lesion when compared
to their sham group ($$ p< 0.01) or the WT ligated group (## p<
0.01). (C) IL-1b transcript level was significantly higher in transgenic
ligated rats at 21 days after lesion when compared to sham
littermates ($$$ p< 0.001) or WT ligated rats (## p< 0.01). Each
group included 5 rats, ANOVA and Tukey post-hoc test as statistical
analyses.
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hSOD1G93A rats show impaired astroglial response in the
spinal dorsal horn after PSNL
Consistent with previous investigations, PSNL induced
an up-regulation of GFAP on the ipsilateral side of the
spinal cord in WT rats [47,48]. However, such GFAP
up-regulation appeared lower in hSOD1G93A rats. Con-
sidering the increased lesion-associated hypersensitivity
in these rats, this suggests that astrocytes do not exclu-
sively exhibit pro-nociceptive effects in models of neuro-
pathic pain. Indeed, it was already demonstrated that
intrathecal grafting of PKC-activated astrocytes failed to
induce pain behaviors [39]. Moreover, an inverse corre-
lation has been reported between the intensity of
mechanical hypersensitivity and GFAP immunoreactivity
in the substantia gelatinosa at 3 months following com-
plete sciatic nerve transection [49]. Hence, it cannot be
excluded that the attenuated GFAP up-regulation in
transgenic animals with PSNL may, to some extent, sup-
port the higher degree of neuropathic pain symptoms in
these animals. The mechanisms involved in the attenua-
tion of astroglial activation remain to be elucidated, but
it is already known that the nature of cytokines is deter-
minant in the resulting influence on astroglial reactivity
[50]. Thus, it may be hypothesized that microglia, via
the adopted activation state and the corresponding pat-
tern of mediator expression, are able to differently drive
astroglial responses. Of interest, IL-1b, which was clearly
increased in transgenic rats at 21 days post PSNL, has
previously been shown to decrease GFAP expression in
vitro [51,52].
Glutamate clearance system is improved in the dorsal
horn of hSOD1G93A animals after PSNL
Glutamate transporter expression is influenced by a
variety of factors, particularly inflammatory mediators
[13,14,53]. Altered expression of glutamate transporters
was already evidenced in several CNS pathologies
[54-56], as well as in neuropathic pain models [57-59].
Biphasic regulation of these transporters has been
reported after nerve injury with an up-regulation in the
first days and a down-regulation at 2 weeks [12,60,61].
Glutamate transporter down-regulation was suggested
to enhance pain hypersensitivity due to impaired gluta-
mate handling. We found that GLAST and GLT-1 were
both up-regulated at 21 days after PSNL in transgenic
rats and, accordingly, uptake activity was found to be
increased. Although surprising at first glance, these find-
ings might be related to differential expression in astro-
glia and microglia, as it was previously reported after
PSNL [62]. Indeed, while in astrocytes, GLAST and
GLT-1 immunoreactivity was decreased, microglia on
the other hand showed a de novo synthesis of both glu-
tamate transporters, in accordance with other in vitro
[63,64] and in vivo [65] studies. The increased microglial
expression of glutamate transporters may explain the
overall increased uptake in transgenic ligated rats.
Importantly, because transgenic rats showed increased
pain hypersensitivity and microglial activation after
PSNL, it suggests that microglia would not play a major
role in regulating glutamate transmission.
Conclusion
Even though increased processing of experimental noci-
ceptive stimuli was recently evidenced in ALS patient
[66], the study of pain in the context of ALS was out of
the scope of the present research which essentially took
advantage of the characteristic of an animal model of
the disease at a pre-symptomatic stage. Thus, we here
demonstrated that rats expressing hSOD1G93A develop
more severe pain hypersensitivity after peripheral nerve
injury. Although this finding may be explained by a vari-
ety of cellular and molecular mechanisms, our data sug-
gest the involvement of specific microglial activation
states such as those characterized by TLR4 and Nox2
gene up-regulation, leading to an exacerbated inflamma-
tory and nitroxidative environment. Moreover, sustained
increases in IL-1b gene expression may also participate
in the enhanced pain hypersensitivity. On the other
hand, because astroglial activation was found to be atte-
nuated in transgenic ligated rats, one may propose that
activated astrocytes do not necessarily exert pro-noci-
ceptive effects. Finally, the glutamate clearance system is
affected in transgenic rats and this may additionally
impact on the processing of pain signals in the spinal
dorsal horn. The use of an animal model with SOD1
mutation showing more severe pain hypersensitivity and
enhanced microglial activation after nerve injury may
open new avenues in understanding neuropathic pain
mechanisms.
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